#4

RECEIVED

OIPE

NOV 1 3 2001

RAW SEQUENCE LISTING

DATE: 05/04/2 JECH CENTER 1600/2900

ENTERED

PATENT APPLICATION: US/09/842,347

TIME: 12:40:33

Input Set : N:\Crf3\RULE60\09842347.txt
Output Set: N:\CRF3\05042001\I842347.raw

SEQUENCE LISTING

```
4 (1) GENERAL INFORMATION:
             (i) APPLICANT: TAKAHASHI, Tohru
                             SERIZAWA, Nobufusa
      8
                             KOISHI, Ryuta
      9
                             KAWASHIMA, Ichiro
     11
            (ii) TITLE OF INVENTION: EXPRESSION SYSTEMS UTILIZING
                                      AUTOLYZING FUSION PROTEINS
     12
                                      AND A NOVEL REDUCING POLYPEPTIDE
     13
           (iii) NUMBER OF SEQUENCES: 19
     15
            (iv) CORRESPONDENCE ADDRESS:
     17
                  (A) ADDRESSEE: Frishhauf, Holtz, Goodman, Langer & Chick, P.C.
     18
                  (B) STREET: 767 Third Avenue-25th Floor
     19
     20
                  (C) CITY: New York
                   (D) STATE: New York
     21
     22
                   (E) COUNTRY: United States
     23
                   (F) ZIP: 10017-2023
     25
             (v) COMPUTER READABLE FORM:
                   (A) MEDIUM TYPE: Floppy disk
     26
                   (B) COMPUTER: IBM PC compatible
     27
     28
                  (C) OPERATING SYSTEM: PC-DOS/MS-DOS
     29
                  (D) SOFTWARE: PatentIn Release #1.24
     31
            (vi) CURRENT APPLICATION DATA:
C--> 32
                  (A) APPLICATION NUMBER: US/09/842,347
C--> 33
                  (B) FILING DATE: 25-Apr-2001
     34
                  (C) CLASSIFICATION:
     44
           (vii) PRIOR APPLICATION DATA:
                  (A) APPLICATION NUMBER: 09/167,151
     37
                  (B) FILING DATE:
     38
     41
                  (A) APPLICATION NUMBER: JP 6-218392
                  (B) FILING DATE: 13-SEP-1994
     42
     45
                  (A) APPLICATION NUMBER: JP 6-303809
     46
                  (B) FILING DATE: 07-DEC-1994
     48
          (viii) ATTORNEY/AGENT INFORMATION:
     49
                  (A) NAME: Goodman, Herbert
                  (B) REGISTRATION NUMBER: 17081
     50
                  (C) REFERENCE/DOCKET NUMBER: 950376/HG
     51
            (ix) TELECOMMUNICATION INFORMATION:
     53
                  (A) TELEPHONE: (212) 319-4900
     55
                  (B) TELEFAX: (212) 319-5101
     56
                  (C) TELEX: 236268
        (2) INFORMATION FOR SEQ ID NO: 1:
     59
     61
             (i) SEQUENCE CHARACTERISTICS:
                  (A) LENGTH: 1320 base pairs
     62
                  (B) TYPE: nucleic acid
     63
                  (C) STRANDEDNESS: double
     64
```

(D) TOPOLOGY: linear

5/4/01

65

RAW SEQUENCE LISTING PATENT APPLICATION: US/09/842,347

DATE: 05/04/2001

TIME: 12:40:33

| | 67 | | /;; \ | MOT | .ECIII | יבי ידיע | ישם. | CDNA | +0 | m D N 7 | | | | | | | | |
|----|-----|--|---------|------|--------|--------------|------|------|-------------|---------|------|------|------|--------|-------|-------|-----------|-----|
| W> | | (ii) MOLECULE TYPE: cDNA to mRNA (iii) HYPOTHETICAL: N | | | | | | | | | | | | | | | | |
| W> | | (iv) ANTI-SENSE: N | | | | | | | | | | | | | | | | |
| W/ | 73 | | | | | AL SC | | | | | | | | | | | | |
| | 74 | | (* +) | | | RGANI | | | er V | 'ello | w Ve | in V | irus | : | | | | |
| | 76 | | (ix) | FEA | | | | 010. | C. 1 | | ,,, | | | | | | | |
| | 77 | | (-1.) | | | AME/K | EY. | CDS | | | | | | | | | | |
| | 78 | | | | | CATI | | | 320 | | | | | | | | | |
| | 79 | | | | • | HER | | | | | | | | | | | | |
| | 80 | | (ix) | | | | | | | | | | | | | | | |
| | 81 | | (=) | | | ME/K | EY: | mat | pept | ide | | | | | | | | |
| | 82 | | | • | • | CATI | | | | | | | | | | | | |
| | 83 | | | • | • | HER | | | | | | | | | | | | |
| | 87 | | (xi) | | | E DE | | | | | D NC | : 1: | | | | | | |
| | 89 | AAG | | | | AAA | | | | | | | | TTG | AAG | TTC | AGA | 48 |
| | 90 | Lys | Phe | Gln | Gly | Lys | Ser | Lys | Arg | Thr | Arg | Gln | Lys | Leu | Lys | Phe | Arg | |
| | 91 | 1 | | | | 5 | | | | | 10 | | | | | 15 | | |
| | 93 | GCG | GCA | AGA | GAC | ATG | AAG | GAT | CGT | TAT | GAA | GTG | CAT | GCC | GAT | GAG | GGG | 96 |
| | 94 | Ala | Ala | Arg | Asp | Met | Lys | Asp | Arg | Tyr | Glu | Val | His | Ala | Asp | Glu | Gly | |
| | 95 | | | | 20 | | | | | 25 | | | | | 30 | | | |
| | 97 | ACT | TTA | GTG | GAA | AAT | TTT | GGA | ACT | CGT | TAT | TCA | AAG | AAA | GGC | AAG | ACA | 144 |
| | 98 | Thr | Leu | Val | Glu | Asn | Phe | Gly | Thr | Arg | Tyr | Ser | Lys | Lys | Gly | Lys | Thr | |
| | 99 | | | 35 | | | | | 40 | | | | | 45 | | | | |
| | | | | | | | | | | | | | | | | | AAC | 192 |
| | | - | - | | Val | . Val | Gly | | _ | Ala | Lys | Thr | _ | _ | Phe | Thr | Asn | |
| | 103 | | 50 | | | | | 55 | | | | | 60 | | | | a | 240 |
| | | | | | | | | | | | | | | | | | GAT | 240 |
| | | | | GIA | Pne | asp | | | . GIU | туг | Ser | | | Arg | туг | Leu | Asp 80 | |
| | 107 | | | 300 | ССП | | 70 | | CAM | C 3 3 | 7.00 | 75 | | C 2 C | 2 2 1 | C m x | | 288 |
| | | | | | | 'GCA 'Ala | | | | | | | | | | | | 200 |
| | 111 | | TIC | 1111 | GIY | 85 | | пес | . дор | GIU | 90 | | 110 | . 1113 | ASII | 95 | | |
| | | | GTT. | ССТ | GAG | | | GGC | GAC | ΔΤΔ | | | CAT | АТС | GTT | | AAG | 336 |
| | | | | | | His | | | | | | | | | | | | |
| W> | | | | 100 | | | | 011 | 105 | | | | 1100 | | 110 | | | |
| | | | TTA | | | AAA | CAG | CAC | | | CTC | AAG | AGA | CCA | | | TGT | 384 |
| | | | | | | Lys | | | | | | | | | | | | |
| W> | | | | 115 | _ | * | | | 120 | | | • | | 125 | | | - | |
| | 121 | TAC | TTT | GTA | AAG | GAT | GCT | GGT | CAG | AAG | GTG | ATG | AGG | ATT | GAT | CTA | ACA | 432 |
| | 122 | Tyr | Phe | Val | Lys | Asp | Ala | Gly | Gln | Lys | Val | Met | Arg | Ile | Asp | Leu | Thr | |
| W> | | | 130 | | _ | | | 135 | | | | | 140 | | | | | |
| | 125 | CCC | CAC | AAC | CCA | TTG | TTG | GCA | AGC | GAT | GTT | AGC | ACA | ACC | ATA | ATG | GGT | 480 |
| | 126 | Pro | His | Asn | Pro | Leu | Leu | Ala | Ser | Asp | Val | Ser | Thr | Thr | Ile | Met | Gly | |
| W> | 127 | 145 | | | | | 150 | | | | | 155 | | | | | 160 | |
| | | | | | | | | | | | | | | | | | TTA | 528 |
| | 130 | Tyr | Pro | Glu | Arg | Glu | Gly | Glu | Leu | Arg | Gln | Thr | Gly | Lys | Ala | Arg | Leu | |
| W> | | | | | | 165 | | | | | 170 | | | | | 175 | | |
| | | | | | | | | | | | | | | | | | GAG | 576 |
| | 134 | Val | Asp | Pro | Ser | Glu | Leu | Pro | Ala | Arg | Asn | Glu | Asp | Ile | Asp | Ala | Glu | |
| | | | | | | | | | | | | | | | | | | |

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/842,347

DATE: 05/04/2001 TIME: 12:40:33

| W> | | | | 3 C III | 180 | | 000 | 3 m 3 | 3 C III | 185 | mm.c | 000 | a | m a m | 190 | 000 | 3 000 | 624 |
|-------|---|--------------|---------------|----------------|---------|-------|------|-------|----------|------|------------------|-------|----------|---------|-------|-------------|-------|--------------|
| | | | | | | | | | | | TTG | | | | | | | 624 |
| | | Pne | GIU | | Leu | Asn | Arg | TTE | | GIY | Leu | Arg | Asp | | Asn | Pro | ire | |
| W> | | | | 195 | | maa | mma | am. | 200 | 330 | a. a | max | | 205 | a | | a. a | . 670 |
| | | | | | | | | | | | GAG | | | | | | | 672 |
| | | | | Asn | vaı | Cys | Leu | | Thr | Asn | Glu | Ser | | GLY | HIS | Arg | GIU | |
| M> | | | 210 | mmm | ~~~ | | | 215 | 000 | ma. | oma | 3.00 | 220 | | | <i>a</i> ., | ~ m | 700 |
| | | | | | | | | | | | GTG | | | | | | | 720 |
| | | _ | Met | Phe | GLŸ | шe | | | GLY | Ser | Val | | тте | Thr | Asn | GIn | | |
| M> | | | | | | | 230 | | a. a | | ma. | 235 | a., | maa | | G 3 TF | 240 | 7.60 |
| | | | | | | | | | | | TCA | | | | | | | 768 |
| | | Leu | Phe | Arg | Arg | | Asn | GLY | GLu | Leu | Ser | тте | GIn | Ser | гàг | | GIY | |
| M> | | | mm.o. | | | 245 | | | | | 250 | | 3.00 | ama | | 255 | a. a | 016 |
| | | | | | | | | | | | TTG | | | | | | | 816 |
| | | Tyr | Pne | Arg | - | Arg | Asn | Thr | Thr | | Leu | ьys | мет | Leu | | Leu | GIU | |
| M> | | 003 | | ~~~ | 260 | mm.c | mma | | ~~~ | 265 | 003 | 3.00 | 03.0 | | 270 | ama | mmm | 064 |
| | | | | | | | | | | | CCA | | | | | | | 864 |
| | | - | His | - | TTE | Leu | Leu | тте | | Leu | Pro | Arg | Asp | | Pro | vaı | Pne | |
| M> | | | ~ | 275 | | | | | 280 | | | ama | a | 285 | | | amm. | 010 |
| | | | | | | | | | | | AGA | | | | | | | 912 |
| | | Pro | | - | ire | Arg | Pne | _ | GIU | Pro | Arg | vaı | _ | Asp | гàг | ire | vaı | |
| M> | | mma | 290 | | 3.03 | 3 3 C | mma | 295 | <i>-</i> | 720 | 3 O M | maa | 300 | 3.00 | 3.00 | ama. | max. | 0.00 |
| | | | | | | | | | | | AGT | | | | | | | 960 |
| | | | val | ser | Thr | Asn | | GIN | GIU | ьys | Ser | | ser | ser | Thr | vaı | | |
| W> | | | maa | 3 O m | 330 | 3 mm | 310 | 202 | СТС | | ma a | 315 | 3.3.0 | mma | ma.c | 770 | 320 | 1000 |
| | | | | | | | | | | | TCA | | | | | | | 1008 |
| T.7 & | | GIU | ser | ser | ASII | | ser | Arg | Val | GIII | Ser | Ald | ASII | Pne | TYL | _ | HIS | • |
| M> | | maa | N M C | ma a | 202 | 325 | CCA | CCA | CAC | mem | 330 GGA | 3 3 C | ccm | N III C | cmm | 335 | а Ст | 1056 |
| | | | | | | | | | | | | | | | | | | 1036 |
| W> | | ттр | TIE | ser | 340 | Val | Ата | GIY | urs | 345 | Gly | ASII | ь́то | Met | 350 | ser | TIII | |
| W> | | 7 7 7 | CAM | CCA | | y m m | СШХ | CCT | አጥሮ | | AGT | CTTT | ССП | ጥርን | | አሮአ | CCC | 1104 |
| | | | | | | | | | | | Ser | | | | | | | 1104 |
| W> | | цуз | кар | 355 | riie | 116 | Val | GIY | 360 | птэ | 261 | пец | ALG | 365 | пеп | TIIT | GIY | |
| W> | | CAC | CTT | | ΔТС | ጥጥሮ | ልሮል | AGC | | CCG | CCG | CAG | ጥጥጥ | | λλα | ΔΔΔ | ጥልጥ | 1152 |
| | | | | | | | | | | | Pro | | | | | | | 1132 |
| W> | | - | 370 | HSH | 110 | THE | 1111 | 375 | 1 110 | 110 | 110 | 0111 | 380 | OIU, | 11511 | נעם | -1- | |
| " , | | | | AAG | СТС | AGT | GAA | | ACA | TGG | TGT | AGT | | TGG | AAA | СТА | ААТ | 1200 |
| | | | | | | | | | | | Cys | | | | | | | 1200 |
| W> | | | 0 -111 | J, J | 200 | 001 | 390 | | | | O _I D | 395 | 011 | | _,, | | 400 | |
| | | | GGA | AAG | ΑͲͲ | AGT | | GGT | GGA | АТС | AAC | | GTG | GAG | GAT | GCA | | 1248 |
| | | | | | | | | | | | Asn | | | | | | | |
| W> | | | 0-1 | | | 405 | | 0-1 | 011 | | 410 | | | | | 415 | | |
| | | GAA | GAG | CCC | ттт | | ACA | TCC | AAG | ATG | GCA | AGC | СТТ | СТТ | AGT | | TTG | 1296 |
| | | | | | | | | | | | Ala | | | | | | | |
| W> | | | | | 420 | | | | | 425 | | | | | 430 | P | | |
| • | _ | AAT | TGT | TCA | | CAA | GCA | AGT | GCG | | | | | | | | | 1320 |
| | | | | | | | | Ser | | | | | | | | | | - |
| W> | | | | 435 | | | | | 440 | | | | | | | | | |
| | - | | | | | | | | | | | | | | | | | |

RAW SEQUENCE LISTING DATE: 05/04/2001 PATENT APPLICATION: US/09/842,347 TIME: 12:40:33

```
202 (2) INFORMATION FOR SEQ ID NO: 2:
204
         (i) SEQUENCE CHARACTERISTICS:
205
              (A) LENGTH: 440 amino acids
              (B) TYPE: amino acid
206
207
              (D) TOPOLOGY: linear
209
        (ii) MOLECULE TYPE: protein
211
        (vi) ORIGINAL SOURCE:
212
              (A) ORGANISM: Clover Yellow Vein Virus
214
        (ix) FEATURE:
              (A) NAME/KEY: mat_peptide
215
              (B) LOCATION: 4..437
216
              (D) OTHER INFORMATION:
217
        (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
222 Lys Phe Gln Gly Lys Ser Lys Arg Thr Arg Gln Lys Leu Lys Phe Arg
                                         10
225 Ala Ala Arg Asp Met Lys Asp Arg Tyr Glu Val His Ala Asp Glu Gly
                20
                                     25
228 Thr Leu Val Glu Asn Phe Gly Thr Arg Tyr Ser Lys Lys Gly Lys Thr
           35
                                40
231 Lys Gly Thr Val Val Gly Leu Gly Ala Lys Thr Arg Arg Phe Thr Asn
232 50
                             55
                                                 60
234 Met Tyr Gly Phe Asp Pro Thr Glu Tyr Ser Phe Ala Arg Tyr Leu Asp
                         70
237 Pro Ile Thr Gly Ala Thr Leu Asp Glu Thr Pro Ile His Asn Val Asn
                     85
                                         90
240 Leu Val Ala Glu His Phe Gly Asp Ile Arg Leu Asp Met Val Asp Lys
                                    105
                100
243 Glu Leu Leu Asp Lys Gln His Leu Tyr Leu Lys Arg Pro Ile Glu Cys
           115
                                120
246 Tyr Phe Val Lys Asp Ala Gly Gln Lys Val Met Arg Ile Asp Leu Thr
                            135
                                                140
249 Pro His Asn Pro Leu Leu Ala Ser Asp Val Ser Thr Thr Ile Met Gly
                        150
                                            155
252 Tyr Pro Glu Arg Glu Gly Glu Leu Arg Gln Thr Gly Lys Ala Arg Leu
                   165
                                        170
                                                            175
255 Val Asp Pro Ser Glu Leu Pro Ala Arg Asn Glu Asp Ile Asp Ala Glu
               180
                                    185
                                                        190
258 Phe Glu Ser Leu Asn Arg Ile Ser Gly Leu Arg Asp Tyr Asn Pro Ile
           195
                                200
261 Ser Gln Asn Val Cys Leu Leu Thr Asn Glu Ser Glu Gly His Arg Glu
      210
                            215
                                                220
264 Lys Met Phe Gly Ile Gly Tyr Gly Ser Val Ile Ile Thr Asn Gln His
                       230
                                            235
267 Leu Phe Arg Arg Asn Asn Gly Glu Leu Ser Ile Gln Ser Lys His Gly
                   245
                                        250
270 Tyr Phe Arg Cys Arg Asn Thr Thr Ser Leu Lys Met Leu Pro Leu Glu
              260
                                    265
273 Gly His Asp Ile Leu Leu Ile Gln Leu Pro Arg Asp Phe Pro Val Phe
                                280
            275
```

RAW SEQUENCE LISTING DATE: 05/04/2001 PATENT APPLICATION: US/09/842,347 TIME: 12:40:33

```
276 Pro Gln Lys Ile Arg Phe Arg Glu Pro Arg Val Asp Asp Lys Ile Val
           290
                                 295
     279 Leu Val Ser Thr Asn Phe Gln Glu Lys Ser Ser Ser Thr Val Ser
     280 305
                             310
     282 Glu Ser Ser Asn Ile Ser Arg Val Gln Ser Ala Asn Phe Tyr Lys His
                         325
                                              330
     285 Trp Ile Ser Thr Val Ala Gly His Cys Gly Asn Pro Met Val Ser Thr
                                                              350
                     340
                                         345
     288 Lys Asp Gly Phe Ile Val Gly Ile His Ser Leu Ala Ser Leu Thr Gly
          355
                                     360
                                                          365
     291 Asp Val Asn Ile Phe Thr Ser Phe Pro Pro Gln Phe Glu Asn Lys Tyr
                                 375
     294 Leu Gln Lys Leu Ser Glu His Thr Trp Cys Ser Gly Trp Lys Leu Asn
                             390
                                                  395
     297 Leu Gly Lys Ile Ser Trp Gly Gly Ile Asn Ile Val Glu Asp Ala Pro
                         405
                                             410
     300 Glu Glu Pro Phe Ile Thr Ser Lys Met Ala Ser Leu Leu Ser Asp Leu
                     420
                                         425
     303 Asn Cys Ser Phe Gln Ala Ser Ala
     304
                 435
     306 (2) INFORMATION FOR SEQ ID NO: 3:
     308
             (i) SEQUENCE CHARACTERISTICS:
                   (A) LENGTH: 25 base pairs
     309
     310
                   (B) TYPE: nucleic acid
                   (C) STRANDEDNESS: single
     311
     312
                   (D) TOPOLOGY: linear
     314
             (ii) MOLECULE TYPE: other nucleic acid, synthetic DNA
W--> 316
            (iii) HYPOTHETICAL: N
W--> 318
             (iv) ANTI-SENSE: N
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
                                                                               25
     324 GTCCATGGGG AAAAGTAAGA GAACA
     326 (2) INFORMATION FOR SEQ ID NO: 4:
     328
              (i) SEQUENCE CHARACTERISTICS:
     329
                   (A) LENGTH: 20 base pairs
     330
                   (B) TYPE: nucleic acid
                   (C) STRANDEDNESS: single
     331
     332
                   (D) TOPOLOGY: linear
     334
             (ii) MOLECULE TYPE: other nucleic acid, synthetic DNA
W--> 336
            (iii) HYPOTHETICAL: N
W--> 338
             (iv) ANTI-SENSE: N
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
     342
     344 ACTCTGAGAC CGTGCTCGAG
                                                                               20
     346 (2) INFORMATION FOR SEQ ID NO: 5:
              (i) SEQUENCE CHARACTERISTICS:
    349
                   (A) LENGTH: 20 base pairs
    350
                   (B) TYPE: nucleic acid
    351
                   (C) STRANDEDNESS: single
    352
                   (D) TOPOLOGY: linear
    354
             (ii) MOLECULE TYPE: other nucleic acid, synthetic DNA
```

VERIFICATION SUMMARY
PATENT APPLICATION: US/09/842,347

DATE: 05/04/2001 TIME: 12:40:34

```
L:32 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:]
 L:33 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:]
 L:69 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=1
 L:71 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=1
 L:115 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:119 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:123 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:127 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:131 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:135 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:139 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:143 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:147 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:151 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:155\ M:336\ W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:159 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:163 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:167 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
 L:171 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:175 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:179 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:183 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:187\ M:336\ W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:191 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:195 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:199 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:316 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=3
L:318 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=3
L:336 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=4
L:338 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=4
L:356 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=5
L:358 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=5
L:376 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=6
L:378 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=6
L:396 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=7
L:398 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=7
L:416 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=8
L:418 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=8
L:436 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=9
L:455 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=10
L:474 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=11
L:476 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=11
L:476 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=11
L:769 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=13
L:771 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=13
L:789 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=14
L:791 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=14
L:811 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=15
L:813 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=15
```

VERIFICATION SUMMARY

DATE: 05/04/2001 TIME: 12:40:34

PATENT APPLICATION: US/09/842,347

Output Set: N:\CRF3\05042001\1842347.raw

Input Set : N:\Crf3\RULE60\09842347.txt

L:831 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=16
L:833 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=16
L:851 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=17
L:853 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=17
L:871 M:246 W: Invalid value of Alpha Sequence Header Field, [HYPOTHETICAL:], SeqNo=18
L:873 M:246 W: Invalid value of Alpha Sequence Header Field, [ANTI-SENSE:], SeqNo=18
L:894 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19